Autolus Therapeutics (AUTL) announced that Autolus will assess the feasibility of Cellares’ Cell Shuttle platform to complement its commercial ...
Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...
Bringing the bispecific T-cell engager into the frontline consolidation phase "redefines the standard of care" for patients with B-ALL, an investigator said. FDA has approved blinatumomab, a ...
Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.
Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...
News-Medical.Net on MSN
Epigenetic plasticity in germinal center B cells may help explain lymphoma origins
Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...
Autolus will evaluate Cellares' fully automated, high-throughput manufacturing platform in preparation for expansion into new indications Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback